Blog: CYCLERION THERAPEUTICS, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K) –

Item 7.01 Regulation FD Disclosure.

On July 28, 2022, Cyclerion Therapeutics, Inc. (the “Company”) announced topline
data from its CY6463 Cognitive Impairment Associated with Schizophrenia (“CIAS”)
study. Copies of the press release and CIAS clinical data presentation are being
furnished as Exhibit 99.1 and Exhibit 99.2, respectively to this Current Report
on Form 8-K.
The information contained in Item 7.01 of this Current Report on Form 8-K,
Exhibit 99.1 and Exhibit 99.2 attached hereto is intended to be furnished and
shall not be deemed “filed” for purposes of Section 18 of the Securities
Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the
liabilities of that section, nor shall it be deemed incorporated by reference in
any filing under the Securities Act of 1933, as amended, or the Exchange Act,
except as expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.


Exhibit No.                                 Description

  99.1           Press Release of Cyclerion Therapeutics, Inc. dated July 28, 2022
  99.2           CIAS Clinical Data Presentation of Cyclerion Therapeutics, Inc.,
               dated July 28, 2022
104            Cover Page Interactive Data File



© Edgar Online, source Glimpses

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s